Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462314 · ClinicalTrials.gov registry record
Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
A clinical trial, sponsored by Viome.
- Completed
- Registry status
- 24
- Enrollment target
NCT05462314 is a clinical trial that has completed, run by Viome. The registered enrollment target is 24 participants.
The verdict
NCT05462314 has completed, sponsored by Viome.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The primary objective of this prospective observational study is to characterize the gut and oral microbiome as well as the whole blood transcriptome in gastrointestinal cancer patients and correlate these findings with cancer type, treatment efficacy and toxicity. Participants will be recruited from existing clinical sites only, no additional clinical sites are needed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2025-01-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05462314
The ClinicalTrials.gov registry entry for NCT05462314 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viome, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05462314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05462314 about?
NCT05462314 is a clinical study titled "Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies". The primary objective of this prospective observational study is to characterize the gut and oral microbiome as well as the whole blood transcriptome in gastrointestinal cancer patients and correlate these findings with cancer type, treatment efficacy and toxicity. Participants will be recruited fro...
What is the current status of trial NCT05462314?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2022-03-29. Estimated completion is 2025-01-21.
Who is sponsoring clinical trial NCT05462314?
This trial is sponsored by Viome, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.